Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Analysts at Alliance Global Partners dropped their FY2024 earnings per share estimates for shares of Curaleaf in a research note issued to investors on Wednesday, October 30th. Alliance Global Partners analyst A. Grey now expects that the company will post earnings per share of ($0.27) for the year, down from their prior forecast of ($0.26). The consensus estimate for Curaleaf's current full-year earnings is ($0.24) per share. Alliance Global Partners also issued estimates for Curaleaf's Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.21) EPS.
Curaleaf (OTCMKTS:CURLF - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). Curaleaf had a negative return on equity of 14.75% and a negative net margin of 18.59%. The business had revenue of $342.29 million for the quarter, compared to analyst estimates of $344.57 million.
Several other analysts have also weighed in on the company. Cormark raised Curaleaf from a "hold" rating to a "moderate buy" rating in a report on Monday, August 12th. Needham & Company LLC reissued a "buy" rating and issued a $6.25 price objective on shares of Curaleaf in a research note on Thursday, August 8th.
Check Out Our Latest Report on Curaleaf
Curaleaf Stock Performance
OTCMKTS CURLF traded up $0.07 during trading on Friday, hitting $2.96. The company's stock had a trading volume of 386,061 shares, compared to its average volume of 669,206. The company has a quick ratio of 0.50, a current ratio of 1.09 and a debt-to-equity ratio of 0.83. The firm has a 50 day moving average price of $3.01 and a 200 day moving average price of $3.89. The firm has a market cap of $1.92 billion, a P/E ratio of -8.46 and a beta of 0.84. Curaleaf has a 52 week low of $2.70 and a 52 week high of $6.40.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Further Reading
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.